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Summary
Background Disease-modifying treatments are in development for Huntington’s disease; crucial to their success is to identify 
a timepoint in a patient’s life when there is a measurable biomarker of early neurodegeneration while clinical function is 
still intact. We aimed to identify this timepoint in a novel cohort of young adult premanifest Huntington’s disease gene 
carriers (preHD) far from predicted clinical symptom onset.
Methods We did the Huntington’s disease Young Adult Study (HD-YAS) in the UK. We recruited young adults with 
preHD and controls matched for age, education, and sex to ensure each group had at least 60 participants with imaging 
data, accounting for scan fails. Controls either had a family history of Huntington’s disease but a negative genetic test, 
or no known family history of Huntington’s disease. All participants underwent detailed neuropsychiatric and cognitive 
assessments, including tests from the Cambridge Neuropsychological Test Automated Battery and a battery assessing 
emotion, motivation, impulsivity and social cognition (EMOTICOM). Imaging (done for all participants without 
contraindications) included volumetric MRI, diffusion imaging, and multiparametric mapping. Biofluid markers of 
neuronal health were examined using blood and CSF collection. We did a cross-sectional analysis using general least-
squares linear models to assess group differences and associations with age and CAG length, relating to predicted 
years to clinical onset. Results were corrected for multiple comparisons using the false discovery rate (FDR), with 
FDR <0·05 deemed a significant result.
Findings Data were obtained between Aug 2, 2017, and April 25, 2019. We recruited 64 young adults with preHD and 
67 controls. Mean ages of participants were 29·0 years (SD 5·6) and 29·1 years (5·7) in the preHD and control groups, 
respectively. We noted no significant evidence of cognitive or psychiatric impairment in preHD participants 23·6 years 
(SD 5·8) from predicted onset (FDR 0·22–0·87 for cognitive measures, 0·31–0·91 for neuropsychiatric measures). The 
preHD cohort had slightly smaller putamen volumes (FDR=0·03), but this did not appear to be closely related to predicted 
years to onset (FDR=0·54). There were no group differences in other brain imaging measures (FDR >0·16). CSF 
neurofilament light protein (NfL), plasma NfL, and CSF YKL-40 were elevated in this far-from-onset preHD cohort 
compared with controls (FDR<0·0001, =0·01, and =0·03, respectively). CSF NfL elevations were more likely in individuals 
closer to expected clinical onset (FDR <0·0001).
Interpretation We report normal brain function yet a rise in sensitive measures of neurodegeneration in a preHD cohort 
approximately 24 years from predicted clinical onset. CSF NfL appears to be a more sensitive measure than plasma NfL 
to monitor disease progression. This preHD cohort is one of the earliest yet studied, and our findings could be used to 
inform decisions about when to initiate a potential future intervention to delay or prevent further neurodegeneration 
while function is intact.
Funding Wellcome Trust, CHDI Foundation. 
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Huntington’s disease is an autosomal dominant neuro­
degenerative condition caused by a CAG expansion in the 
HTT gene, resulting in the expression of mutant huntingtin 
protein, which is thought to be the predominant toxic 
agent. Clinically, Huntington’s disease is characterised by 
gradual deterioration of motor and cognitive func tion and 
neuro psychiatric disturbance. In an era of new therapies 
capable of targeting DNA and RNA, the known single 
genetic cause of Huntington’s disease provides an attractive 
target for such treatments, with several huntingtin­lowering 
drugs now in human trials.1,2 An appropriate time to initi­
ate therapy in a preventive trial would be before clinical 
functioning has been affected, but when one or more 
measurable biomarkers of neuro degeneration can be used 
for enrichment or stratification and to monitor efficacy.
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A detailed characterisation of the premanifest period in 
Huntington’s disease is crucial for disease staging, 
informing the optimum time to initiate treatments, and 
identifying biomarkers for future trials in people with 
premanifest Huntington’s disease (preHD). Although the 
most appropriate markers in the earliest premanifest 
period are unknown, the genetic basis of Huntington’s 
disease offers the potential to identify this treatment 
window. First, with complete penetrance, it is possible to 
identify preHD via genetic testing before clinical onset—
ie, the emergence of clear motor manifestations of the 
disease. Second, there are well­established models to 
estimate the time to expected clinical onset by using the 
strong influence of CAG expansion length on age of 
onset.3 These models have shown clear relationships 
between estimated years to clinical onset and several 
biomarkers of neurodegeneration.4
Multisite observational studies in preHD such as 
TRACK­HD,4 PREDICT­HD,5 and ENROLL­HD6 have 
consistently reported subtle motor, cognitive, and neuro­
psychiatric impairments at least 10–15 years before clinical 
onset. At this stage, Huntington’s disease pathology has 
already had a widespread effect on brain structure, with 
extensive evidence of striatal atrophy and white matter 
degeneration.4,5 Elevations in plasma neuro filament light 
protein (NfL) a marker of axonal damage, were noted in 
the TRACK­HD cohort7 and such biofluid markers might 
be among the earliest detectable alterations in Huntington’s 
disease.8 Because the preHD cohorts studied to date 
already show disease effects across these many domains, 
if we are to identify the earliest manifestations of 
Huntington’s disease pathology and establish whether 
there is a time when they are undetectable, we need to look 
back to even earlier in the disease process.
Research in context
Evidence before this study
We reviewed the scientific literature on the premanifest phase 
of Huntington’s disease (preHD), searching PubMed on 
Dec 17, 2019, with no restrictions on start date or language, for 
articles published in the previous 10 years with human adult 
participants and the following search terms: “Huntington 
disease” [MeSH] AND (“prodromal” OR “premanifest” OR 
“presymptomatic” [Title/Abstract]). Our search yielded 
931 studies. We found robust evidence of disease-related 
differences across multiple modalities in preHD up to 15 years 
before expected clinical disease onset. Such differences include 
increases in biofluid biomarkers of neuronal damage, brain 
atrophy focused in the subcortical structures accompanied by 
involvement of white matter networks, and subtle impairment 
in cognition, motor function, and neuropsychiatry. We are not 
aware of studies that include a comprehensive, multimodal 
assessment of adult premanifest gene carriers more than 
20 years from predicted onset.
Added value of this study
Our study presents comprehensive phenotyping of a preHD 
cohort who were on average approximately 24 years from 
predicted onset, compared with a closely matched control 
group. Assessments included detailed cognitive, 
neuropsychiatric, and biofluid biomarker (plasma and CSF) 
assessments and state of the art volumetric and diffusion 
imaging. For the first time in studies of Huntington’s disease, we 
also assessed multiparametric imaging, providing brain 
estimates of myelin and iron, as well as CSF measurements of 
total huntingtin. We noted no detectable motor, cognitive, or 
psychiatric differences in preHD at this stage. Brain imaging did 
not reveal any significant differences in caudate, white matter, or 
cortical grey matter volumes, and there were also no differences 
in diffusion and multiparametric mapping measures. There were, 
however, elevations in CSF mutant huntingtin, neurofilament 
light protein (NfL), YKL-40, and plasma NfL in individuals with 
preHD, alongside reduced putamen volumes. CSF NfL showed 
the strongest effect size of all measures and was the only 
measure associated with predicted years to onset in this cohort, 
with higher values in individuals closer to predicted onset. 
53% of individuals with preHD had CSF NfL values in the normal 
range, suggesting that this biomarker first becomes abnormal 
approximately 24 years from predicted onset. Although CSF 
mutant huntingtin was detectable at low concentrations in 
individuals with preHD, most of these individuals had values 
below the limit of quantification. Total huntingtin 
concentrations were unchanged in individuals with preHD.
Implications of all the available evidence
With several potential disease-modifying treatments in 
development for Huntington’s disease, including mutant and 
total huntingtin-lowering approaches, identifying the optimum 
time to treat and suitable biomarkers for trials in early preHD is 
of timely importance. Our findings suggest that approximately 
24 years from predicted onset, when cognitive and 
neuropsychiatric function appears intact, represents a potentially 
appropriate time to initiate future disease-modifying therapies. 
In such a trial, CSF NfL seems as though it would be the most 
suitable biomarker to monitor progression and, eventually, 
efficacy, showing superior sensitivity than plasma NfL when 
measured far from disease onset contrary to closer to disease 
onset, when sensitivity of CSF and plasma NfL have near 
equivalence. Although putamen volume is also reduced at this 
stage, the smaller effect size and absence of a strong association 
with predicted years to onset could limit its use in clinical trials 
in early preHD. Suppression of CSF mutant huntingtin to 
undetectable concentrations could be a viable measure of target 
engagement for such trials. However, because concentrations of 
mutant huntingtin are frequently only just above the detection 
limit, total huntingtin concentrations could be used to provide 
a measure of percentage huntingtin reduction for total 
huntingtin-lowering trials. These results are likely to have a 
major effect on the direction and design of future clinical trials in 
Huntington’s disease.
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Using state­of­the­art methods, we examined potential 
group differences across multiple domains between healthy 
controls and a preHD cohort far from predicted onset. We 
aimed to assess how early disease­related changes can be 
identified (ie, when there is a measurable biomarker of 
early neurodegeneration but clinical function is still intact), 
and which measures are most sensitive in early preHD.
Methods
Study design and participants
For the Huntington’s disease Young Adult Study 
(HD­YAS) we recruited preHD gene carriers and controls 
from across the UK. PreHD participants required a pre­
vious positive Huntington’s disease genetic test (CAG ≥40) 
but without showing clinical signs of the disease: all had a 
Panel: Assessments in the Huntington’s disease Young Adult Study 
Cognition
CANTAB
• Intra-extra dimensional set shift
• Paired associate learning
• Rapid visual processing
• One touch stockings of Cambridge
• Spatial working memory
• Stop signal task
EMOTICOM






• Symbol digit modalities test
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• Barratt impulsivity scale
• Frontal systems behaviour scale
• MOS 36-item short-form health survey
• Obsessive-compulsive inventory
• Pittsburgh sleep quality index
• Speilberger state–trait anxiety index
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• Neurite density index
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Cambridge Neuropsychological Test Automated Battery (CANTAB)11 and Emotion, 
Motivation, Impulsivity and Social Cognition (EMOTICOM)12 are computerised cognitive 
assessments. CANTAB assesses non-social cognition. EMOTICOM assesses social and 
emotion cognition. Neuropsychiatric measures were obtained from a series of validated 
self-report questionnaires. Volumetric imaging provided volume measures adjusted for 
total intracranial volume. Diffusion tensor imaging,13 NODDI,14 multiparametric mapping,15 
and structural connectivity were measured in specified regions of interest. Regions of 
interest for diffusion tensor imaging and NODDI were the genu, mid-body, and splenium 
of the corpus callosum, anterior and posterior internal capsule, and external capsule. 
Multiparametric mapping included the same regions plus caudate and putamen. 
Connection strength was measured for limbic, executive, and sensorimotor striatum as 
well as rich club regions (hub regions that have the highest number of connections to 
other brain regions in the network). Rich club regions included the inferior parietal, 
superior parietal, precentral, rostral middle frontal, and superior frontal cortices, and the 
thalamus. Efficiency and modularity are whole brain measures of integration and 
segregation, respectively. Assays used for biofluid analysis are in the appendix (p 25). 
Further details for all measures are in the appendix (pp 6–17). MOS=medical outcomes 
survey. NODDI=neurite orientation dispersion and density imaging. GFAP=glial fibrillary 
acidic protein. IL=interleukin. NfL=neurofilament light protein. UCH-L1=ubiquitin 
carboxyl-terminal hydrolase L1. YKL-40 is also known as chitinase 3-like protein 1.
See Online for appendix
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Unified Huntington’s Disease Rating Scale Total Motor 
Score (UHDRS TMS)9 of 5 or less. Exclusion criteria 
included contraindication to MRI scanning, significant 
comorbidity, at­risk genetic status (ie, someone who has 
not had a genetic test but who has a family history of 
Huntington’s disease), and reduced penetrance CAG 
repeat length (ie, 36–39). Disease Burden Score,10 a 
product of age and CAG length, was required to be 240 or 
less, which approximates to more than 18 years from 
predicted clinical onset. CAG lengths were re­measured at 
a single lab for statistical analysis. Controls were gene 
negative (ie, having a family history of Huntington’s 
disease but a negative genetic test), family members with 
no Huntington’s disease risk (eg, partners or spouses of 
gene carriers), or members of the wider Huntington’s 
disease community (recruited through support groups or 
as friends of participants). Gene carriers and controls 
were matched by monitoring group means for sex, age, 
years of education, and SD for age and education as 
recruitment progressed, to aid targeted recruitment. The 
study was approved by the Bloomsbury Research Ethics 
Committee and all partici pants gave written informed 
consent prior to study entry.
Outcomes and procedures
All outcomes by modality are listed in the panel. All 
participants underwent extensive assessment of cognitive 
and neuro psychiatric function, neuroimaging, blood 
sampling, and optional CSF collec tion; full details are in 
the appendix (pp 6–17), and a list is provided in the panel.
A comprehensive battery of neuropsychological tests, 
including from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB)11,16,17 and social and emotional 
cognition and motivation from the Emotion, Motivation, 
Impulsivity and Social Cognition (EMOTICOM) battery,12 
was used. Tests were chosen to measure performance 
across multiple domains for which there was previous 
evidence of impairment in Huntington’s disease, includ­
ing cognitive flexi bility,18 planning,19 verbal fluency,20 emo­
tion recognition,21 inhi bition,22 attention,22 learning,23 and 
memory23,24 (further details in the appendix, pp 6–10).
A comprehensive battery of neuropsychiatric func tion 
was collected using well validated self­report question­
naires, capturing the following domains: dep ress ion, 
anxiety, apathy, sleep, impulsivity, obsessive­com pulsive 
behaviour, frontal behaviour, and general health (panel). 
We did neuroimaging for all enrolled participants when 
possible, but despite initial screening for MRI contra­
indications, some participants were found to be unsuit able 
for scanning on the day of their visit and did not 
undergo MRI scanning. Assessments included volumetric 
T1­weighted imaging, diffusion­weighted imagi ng, and 
novel multiparametric mapping. Volumetric measures of 
whole brain, striatum (putamen and caudate), grey and 
white matter, and the ventricles were derived from 
T1­weighted images; diffusion­weighted imaging data 
were analysed using diffusion tensor imaging13 and neurite 
orientation and dispersion density imaging (NODDI),14 
providing measures of white matter micro struc ture 
within six prespecified regions of interest (panel), which 
were selected based on previous work.25 Multiparametric 
mapping provided assessments of myelin and iron within 
the brain,15 which were analysed within the same regions 
of interest plus caudate and putamen. Structural connect­
ivity metrics were derived from diffusion­weighted imag­
ing for six cortico­striatal measures, 14 cortico­cortical 
connection measures, and two whole brain network 
measures, all in right­handed participants only.
We collected biofluids using standardised, well validated 
conditions, methods, and equipment26 (appendix p 17). 
Total huntingtin (mutant huntingtin and wild type), 
mutant huntingtin, NfL, YKL­40 (also known as Chitinase­
3­like protein), total tau, neurogranin, interleukin­6 (IL­6), 
interleukin­8 (IL­8), glial fibrillary acidic protein (GFAP), 
and ubiquitin carboxyl­terminal hydrolase L1 (UCH­L1) 
were measured in CSF; NfL, total tau, and GFAP were 
measured in plasma.
Statistical analysis
The study had 80% power and a 5% risk of type 1 error to 
reject the primary null hypothesis if, after statistical 
adjustment for covariates, the group difference was 
0·53 within­group standard deviations. This hypothetical 
difference is consistent with the striatal volume difference 
between controls and the group furthest from onset in 
the TRACK­HD study.4
Multiple imputation was used to account for missing 
data (appendix pp 18–19). All measures were processed and 






Age (years) 29·0 (5·6) 29·1 (5·7) 0·95
Sex 0·81
Male 30 (47%) 28 (42%) ··
Female 34 (53%) 39 (58%) ··
Education (years) 16·2 (2·1) 16·3 (2·2) 0·93
NART 102·4 (7·5) 103·5 (8·3) 0·42
UHDRS total motor 
score*
0 (0–0·25) 0 (0–0) NA
Total functional 
capacity†
13 (13–13) 13 (13–13) NA
CAG repeat length 42·2 (1·6) NA NA
Disease burden score 189·3 (39·3) NA NA
Estimated years to onset 23·6 (5·8) NA NA
Values are means (SD), n (%), or median (IQR). Group comparisons were made 
using t tests (age, education, and NART) and χ² tests (sex). NA=not applicable. 
NART=National Adult Reading Test, an estimate for IQ. PreHD=premanifest 
Huntington’s disease. UHDRS=Unified Huntington’s Disease Rating Scale. 
*Motor scores in both groups were low and within previously reported control 
ranges,27,28 confirming the absence of early Huntington’s disease-related motor 
signs. †All participants in both groups had a total functional capacity of 13/13, 
representing no functional impairment, and therefore no p value is provided.
Table: Participant demographic characteristics
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general least­squares linear models to assess possible 
overall group differences and age interactions between 
groups. Within these same models we controlled and tested 
possible differences driven by age­by­CAG interaction 
within the preHD group, since this interaction closely 
relates to predicted years to onset. Covariates included age, 
sex, and age interactions with sex. For cognitive measures, 
we included the national adult read ing test score, an 
estimate of premorbid IQ, and the International Standard 
Classification of Education, an index of the highest level of 
education achieved, as covariates. For volumetric imaging 
measures, total intracranial volume was included as a 
covariate. Associ ations between biofluids and cognitive, 
neuro psychiatric, and imaging measures were investigated. 
We addressed multiple comparisons via the false discovery 
rate (FDR), and considered an FDR estimate of less than 
0·05 to be significant. Exceptions were the relationship 
of mutant huntingtin concentrations to age and CAG 
length—a fundamental a priori hypothesis which was 
assessed with traditional p values. Biofluid measures 
deemed exploratory (total huntingtin, GFAP, and UCH­L1) 
based on the absence of previous published evidence were 
excluded from FDR correction.
Informed by primary hypothesis results, we did further 
analyses: a receiver operator characteristic (ROC) curve 
analysis of YKL­40, CSF, and plasma NfL to assess their 
ability to distinguish preHD participants from controls; 
an age­by­NfL concentration comparison combining the 
HD­YAS and HD­CSF8 study cohorts to generate CAG­
specific curves across the adult lifespan; and a bootstrapped 
comparison of caudate and putamen volumes to test for a 
significant difference in the relationship to gene­carrier 
status (appendix pp 18–19).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We screened 314 individuals for exclusion in this analysis 
and collected data from 131 of these individuals between 
Aug 2, 2017, and April 25, 2019; 183 individuals were 
excluded from the analysis. Common reasons for 
exclusion included a disease burden score of more than 
240 (n=75), contraindications for MRI (n=41), at­risk 
genetic status (n=23), and significant comorbidity (n=11; 
four of which were psychiatric). 23 individuals were not 
included owing to inadequate matching. The final cohort 
comprised 131 participants (64 preHD and 67 controls), 
closely matched for age, sex, and education (table). 
28 controls were gene negative, 29 were family or partners 
with no known risk of Huntington’s disease, and ten were 
Huntington’s disease community members not at risk of 
Figure 1: Radar plot showing (A) cognitive and (B) neuropsychiatric variables in the Huntington’s disease Young Adult Study
The black line shows the standardised mean difference between individuals with premanifest Huntington’s Disease (preHD) and controls, with conventional 
frequentist 95% CI shaded in grey. The red line represents no difference between means (ie, the null hypothesis) and a value within this line represents greater 
impairment in the preHD group. After false discovery rate correction for multiple comparisons, there were no significant group differences in any cognitive or 
neuropsychiatric measures. See appendix for further details of these variables (pp 6–12) and discussion (p 22). AMI=apathy motivation index. BIS=Barratt impulsivity 
scale. ED=extra dimensional. FSBS=frontal systems behavioural scale. IED=intra–extra dimensional set shifting. OCI=obsessive compulsive inventory. OTS=one touch 
stockings. PAL=paired associates learning. RT=reaction time. RVP=rapid visual processing. RVP A’=a signal detection theory measure of target sensitivity, and mean 
response latency. SDMT=symbol digit modalities test. SF36=36-item self-report survey. SST=stop signal task. SWM=spatial working memory. SSTAI=Speilberger 
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Figure 2: Volumetric MRI
Boxplots of standardised residuals (covariate adjusted) for volumes of (A) putamen, (B) caudate, (C) whole brain, 
(D) grey matter, (E) white matter, and (F) ventricles corrected for intracranial volume. Horizontal lines are the 
medians, boxes are upper and lower quartiles, and whiskers are 1·5 × IQR. Putamen volume was significantly reduced 
in individuals with preHD compared with controls (FDR=0·03). None of the other brain measures showed significant 
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Huntington’s disease. The preHD cohort was estimated to 
be a mean 23·6 years (SD 5·8) from clinical disease onset.
61 (91%) of 67 controls and 62 (97%) of 64 preHD 
participants were assessed to be suitable for MRI 
scanning on the day of the procedure and underwent 
neuroimaging. All but one participant had plasma for 
analysis; 109 (83%) of 131 participants also underwent 
optional CSF collection obtained via lumbar puncture 
(breakdown in appendix, p 24). In the interests of 
conciseness, we graphically display only selected results: 
all cognitive and neuropsychiatric results are displayed 
via radar plots; volumetric imaging results are selected as 
the most widely used imaging technique in Huntington’s 
disease and as the only imaging domain showing a 
significant result; biofluid measures that have previously 
shown differences in preHD are displayed, plus total 
huntingtin and neurogranin, which are also of substantial 
interest (total huntingtin is a potential marker of target 
engagement for huntingtin­lowering therapies and 
neuro granin is a marker of synaptic function). Details of 
remain ing results are in the appendix (pp 26–38).
There were no significant differences between preHD 
and controls in any cognitive or neuropsychiatric measure 
(FDR 0·22–0·87, and 0·31–0·91, respectively; figure 1, 
appendix pp 26–29). Within the preHD group, there were 
no significant relationships between cognitive or neuro­
psychiatric variables and predicted years to onset (FDR 
0·12–0·98).
Putamen volumes were significantly smaller in preHD 
participants compared with controls after FDR correc­
tion (FDR=0·03; figure 2). Uncorrected caudate volumes 
were also smaller in preHD participants (p=0·048), but 
the corresponding FDR was non­significant (figure 2). 
Differences were small: the preHD group had 5·5% 
smaller putamen and 4·0% smaller caudate volumes. 
Caudate and putamen volume reduct ion did not show a 
significant relationship with predicted years to onset in 
preHD (FDR corrected value 0·54 for both). There were 
no significant differences between caudate and putamen 
volume reduction (p=0·30), thus we cannot directly 
conclude that the putamen showed more disease­related 
volumetric differences than the caudate. One prom­
inent outlier in the control group had marked NfL 
elevation for which no additional cause was found 
(appendix, p 21).
There were no group differences in other brain imaging 
measures (FDR >0·16). There were no significant group 
differences in volumes of whole brain, grey or white 
matter, or ventricles (figure 2; appendix pp 30), nor white 
matter microstructure as assessed by diffusion tensor 
imaging and NODDI (FDR 0·27–0·98; appendix pp 31–33). 
Multiparametric mapping­derived measures of iron and 
myelin in the striatum and peristriatal white matter 
were also unchanged in preHD (FDR 0·17–0·99; 
appendix, pp 34–35), as were the structural connectivity 
metrics (FDR 0·71–0·99; appendix, pp 36–37). Within the 
preHD group, there were no significant relationships 
between any imaging measure and age and CAG length 
and age­by­CAG interaction (FDR 0·44–0·96).
CSF mutant huntingtin was detectable at low con­
centrations for all mutation carriers except in three 
participants, all of whom had a low disease burden score. 
Higher mutant huntingtin concentrations were associated 
with increasing CAG length, increasing age, and their 
interaction (F[3,51]=2·81, p=0·49). CAG and its interaction 
with age remained significant after controlling for the 
main effect of age (F[2,51]=3·46, p=0·039). However, 
31 (53%) of 58 preHD mutant huntingtin values were 
between the limit of detection and limit of reliable 
quantification (8–25 fM), a range in which the output 
from the assay is not linear. Although this was accounted 
for in our statistical methods, this interaction should be 
interpreted with caution. Total huntingtin concentrations 
were not significantly different between controls and 
preHD (p=0·23).
The preHD cohort had significantly higher con­
centrations of CSF NfL, plasma NfL, and CSF YKL­40 
than the control cohort (FDR <0·0001, FDR=0·01, and 
FDR=0·03, respectively; figure 3). CSF NfL concentrations 
showed a strong association with predicted years to onset 
in preHD (FDR<0·0001), increasing in those closer to 
predicted clinical onset. Plasma NfL did not show a 
significant association with predicted years to onset 
(FDR=0·18). ROC analysis of CSF NfL, plasma NfL, and 
CSF YKL­40 gave areas under the curve of 0·79, 0·65, 
and 0·64, respectively (appendix p 43), implying superior 
discrimination of CSF NfL over plasma NfL and YKL­40 in 
individuals far from predicted clinical onset. 31 gene 
carriers (53%) of 58 had CSF NfL concentrations within 
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the normal control range (95th percentile of controls) and 
55 (87%) of 63 had plasma NfL concentrations within 
normal range. There were no significant differences 
between the preHD and control cohorts for the other 
analytes (FDR 0·48–0·94; appendix p 38).
By combining our HD­YAS data with baseline values 
from the HD­CSF study,8 we modelled NfL trajectories by 
CAG count across an age range of 20–70 years (figure 4), 
showing the age at which NfL is predicted to rise above the 
95th percentile of controls for each given CAG count. 
CSF NfL concentrations increased slowly initially, before 
accelerating as individuals moved close to predicted 
clinical onset, followed by a deceleration later in the 
disease. Plasma NfL showed a similar trajectory, but with 
concentrations remaining within the normal range for 
longer. Correlations between biofluids and all other meas­
ures are in the appendix (p 21).
Discussion
Results from the HD­YAS, in which we used an extensive 
clinical testing battery, advanced neuroimaging, and CSF 
and plasma biofluid analyses suggest that motor, cognitive, 
and psychiatric function are preserved in gene carriers 
approximately 24 years from predicted onset of clinical 
symptoms. There is little evidence of extensive brain 
atrophy, yet elevated concentrations of CSF NfL are 
suggestive of subtle neuronal injury in this cohort. We 
propose that increased CSF NfL and mutant huntingtin 
concentrations might be the earliest detectable path­
ological events in Huntington’s disease. Combining our 
novel findings in young adults with multiple large cohorts, 
we produced an evidence­based predictive schematic of 
disease trajectory (figure 5), extending the timeline for 
pathological changes back to the start of adulthood. This 
model provides crucial new insights into the start of the 
degenerative process and the evolution of disease markers 
over time.
Cognitive deficits have been reported previously 
in premanifest cohorts,4 with the PREDICT­HD study 
suggesting that cognitive function starts to decline around 
15 years before clinical onset.5 Our cognitive battery 
represents a comprehensive assessment of cognition in 
Huntington’s disease, including tasks that have not 
previously been studied in the premanifest stage. Although 
there were some small group differences in measures of 
cognitive flexibility, sustained attention, and emotion 
processing (appendix p 22), none survived multiplicity 
correction. These differences, driven by individuals closer 
to disease onset, might herald incipient disruption of 
executive function. We suggest that measures such as set 
shifting should be included in future large cohort studies, 
since they might prove to be the most sensitive cognitive 
measures in preHD closer to onset. Indeed, in a previous 
study a task with conceptual overlaps involving set­shifting 
showed decline after 6 months in preHD participants 
16 years from predicted onset.37
Increased neuropsychiatric symptoms have also been 
reported extensively in gene carriers,4,38 including in those 
more than 12 years from predicted onset.38 The absence of 
difference in psychiatric symptoms in this cohort is an 
important finding, suggesting that Huntington’s disease 
gene carriers do not have appreciable behavioural symp­
toms simply related to their disease status in early 
adulthood.
We noted little evidence of abnormality in brain 
structure at this stage of Huntington’s disease. By contrast 
with previous work in a preHD cohort,25 there were no 
group differences in standard diffusion and NODDI 
metrics. This finding suggests white matter integrity 
is maintained at this stage, further supported by the 
absence of significance in structural connectivity metrics. 
Previous work has provided indirect evidence of myelin39 
and iron40 disruption in Huntington’s disease, but our 
novel multiparametric mapping did not reveal any 
regional differences between preHD participants and 
controls at this stage of the disease process. Brain atrophy 
has been widely reported in later pre manifest cohorts,5,36 
with caudate atrophy providing the largest effect size of 
any assessment in the TRACK­HD study.36 Both the 
Figure 3: Biofluid measures
Boxplots of standardised residuals (covariate adjusted) of (A) CSF mutant huntingtin, (B) CSF NfL, (C) plasma NfL, 
(D) YKL-40, (E) CSF total tau, (F) CSF neurogranin, (G) CSF IL-6, (H) IL-8, and (I) CSF total huntingtin. Horizontal 
lines are the medians, boxes are upper and lower quartiles, and whiskers are 1·5 × IQR. All analytes were log 
transformed. As expected, mutant huntingtin was undetectable in all controls. There were significant differences 
between individuals with preHD and controls for CSF NfL (FDR<0·0001), plasma NfL (FDR=0·01), and CSF YKL-40 
(FDR=0·03). No other analytes showed significant group differences. FDR=false discovery rate correction. 
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TRACK­HD4 and PREDICT­HD5 studies suggested that 
striatal volumes are reduced compared with controls at 
least 15 years from expected disease onset. We showed 
gene carriers to have significantly smaller putamen 
volumes. However, a statistical com parison of volume 
reduction between striatal subregions did not provide 
robust evidence for the putamen being more affected 
than the caudate. There was little evidence of an 
association between striatal volume and years to onset or 
NfL concen trations, suggesting that this might be a 
neurodevelop mental constitutive difference, which is 
consistent with previously published work in healthy 
child and adolescent Huntington’s disease gene carriers.41 
Alternatively, this might be a result of neurodegeneration 
that is too subtle and variable to show robust associ­
ations with disease burden at this stage; longitudinal 
follow up might help to resolve this question. Never­
theless, the small effect size and absence of associ ation 
with disease burden indicates striatal atrophy might have 
little use as a marker of progression at this stage of 
Huntington’s disease.
Even in this far­from­onset cohort, NfL concentrations 
were significantly increased. NfL concentrations have 
previously been shown to be closely associated with brain 
volumes, clinical scores, and subsequent clinical onset 
and progression in Huntington’s disease.7,8 CSF NfL had 
the highest effect size of any measure in this study and 
was the only measure showing a significant increasing 
association with estimated years to onset. Through 
modelling NfL with age, we showed the approximate age 
at which NfL becomes abnormal for a given CAG length. 
However, 31 preHD participants (53%) had CSF NfL 
concentrations within the 95th percentile of controls, 
suggesting we have identified a crucial point at which CSF 
NfL begins to rise. Our ROC analysis suggested that 
plasma NfL is less sensitive for detecting early neuro­
degeneration in this cohort, with 55 preHD values (87%) 
within the 95th control percentile; this is in contrast 
to the near­equivalence of CSF and plasma NfL in 
manifest Huntington’s disease.
NfL is therefore a potential candidate to provide a 
measure of disease progression in early preHD and 
might eventually be used as a marker of response to 
treatment in future preventive trials. Future trials target­
ing far­from­onset individuals might enrich recruitment 
Figure 4: NfL trajectories
Associations of NfL concentration in (A) CSF and (B) plasma with age and CAG 
repeat count from combined datasets of HD-YAS and HD-CSF8 (where 
CAG=Huntington’s disease gene carriers’ CAG repeat counts). Data were 
modelled with a polynomial function of age, CAG repeat counts, their squares, 
and their interactions. NfL concentrations were reverse-transformed from log 
NfL values. CAG repeat counts are coloured separately and labelled on the right of 
the image. Shaded in grey is the range between the control curve (dark grey line) 
and the 95th prediction interval of controls. Dashed arrows show the intercept of 
NfL trajectory in Huntington’s disease and the 95th prediction interval of 
controls, representing the age at which NfL concentrations become abnormal. 
Coloured diamonds show the mean age of clinical onset for each CAG based on 
the Langbehn equation using previously published data.3 Further details are in 
























































Figure 5: Disease trajectory in Huntington’s disease from early adulthood to 
manifest disease4,5,8,27–36
Evidence-based predictive schematic, with biofluid changes shown in red, brain 
volumetrics in blue, and functional performance in green. The label HD-YAS 
shows the range of years to estimated onset represented in our study. NfL and 
mutant huntingtin are the first pathological changes, occurring at around 
24 years before expected symptom onset, with slow increases for approximately 
10 years, followed by an acceleration (data from the HD-YAS and the HD-CSF 
study).8 Striatal volumes are slightly smaller than those of age-matched controls 
at the beginning of adulthood (data from the HD-YAS) and start to decline 
around 18 years before expected symptom onset. Decline is approximately 
linear,29 and volume reduction is around 50% of control volume by the time of 
clinical onset.30 White matter volume is reduced4 and shows higher rates of 
atrophy31,32 than in controls by around 15 years before symptom onset, following 
a non-linear trajectory.29 Grey matter loss extends beyond the striatum later, at 
around 10 years before symptom onset,4,33 after which it progresses non-
linearly.29 Soft motor signs in the form of increased variability in voluntary 
movements are apparent by 15 years before symptom onset4–6,27 and increase 
non-linearly.29,34 Cognitive changes start to emerge approximately 15 years 
before expected clinical symptom onset,4,5,35 declining slowly31,36 following a non-
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by using age and CAG length (eg, using the CAG­age­
product score) and NfL above a pre­defined cutoff to 
increase the likelihood of seeing measurable change over 
a typical trial timeframe. The use of NfL as an enrichment 
marker requires further validation, and there are still 
uncertainties regarding the use of NfL as a marker of 
response to treatment. Early data from an antisense 
oligonucleotide trial2 reported transiently increased CSF 
NfL in response to huntingtin­lowering treatment. We 
will develop a better understanding of NfL’s response to 
therapeutic interventions as its performance in numerous 
clinical trial programmes becomes apparent, alongside 
the performance of each therapy. Although non­specific 
to Huntington’s disease, the usefulness of NfL is 
strengthened in this case since individuals with incipient 
mutant huntingtin neuro pathology can be reliably identi­
fied by genetic testing, and other neurodegenerative and 
neurovascular diseases are rare in the age ranges studied 
in this cohort. Despite its practical and cost advantages, 
plasma NfL might not be as sensitive as CSF NfL in 
early preHD.
A key aim of current therapies in development for 
Huntington’s disease is to reduce mutant huntingtin in 
the nervous system, which has already been successfully 
used as a marker of target engagement for current trials of 
huntingtin­lowering therapies in manifest Huntington’s 
disease.2 In our cohort, further from predicted onset, 
mutant huntingtin concentrations were lower than 
previous reports.8,26 Only 23 gene carriers (40%) had 
concentrations above the limit of reliable quantification. 
This finding suggests that, although suppression of 
mutant huntingtin could be a viable measure of target 
engagement for clinical trials at this early stage, it would 
be unable to quantify the percentage of huntingtin­lowering 
to assess dose­response. The presence of the mutant 
HTT gene did not have any effect on total huntingtin 
concentrations; total huntingtin concentrations in CSF 
have not, to our knowledge, been examined in controls 
and Huntington’s disease mutation carriers before. 
With concentrations consistently above the limit of 
quantification, this measure might provide a more reli­
ably quantified marker of target engagement in total 
huntingtin­lowering therapies than mutant huntingtin at 
this early stage.
Our finding of increased concentrations of YKL­40 in 
preHD and their close association with CSF mutant 
huntingtin and NfL suggests astrocytic activation, due 
to mutant huntingtin­induced neuronal injury or cell­
autonomous effects of mutant huntingtin astrocytes.42 
ROC analysis suggested that YKL­40 is less sensitive or 
specific than plasma and CSF NfL in early preHD 
(appendix p 43). Tau,43 IL­6, and IL­8,44 which were 
previously reported to be increased in preHD, were not 
significantly different in this preHD cohort further from 
predicted clinical onset (appendix p 23).
Our study has implications not only for our under­
standing of Huntington’s disease processes, but also in 
identifying the optimum time for treatment interven­
tions. Ideally in the future, effective treatments will be 
administered before widespread neuronal damage, but 
there is likely to be a complex trade­off between the 
benefits of slowing the disease at that point and any 
negative effects of long­term treatment. This risk­benefit 
decision will also vary depending on the nature of the 
treatment and the circumstances of the gene carrier.
With respect to limitations, our study was powered to 
detect plausible disease­related changes in striatal volumes, 
and it might have been underpowered to detect associations 
with age and CAG repeat length. Given our sample size, 
our negative findings suggest an absence of substantial 
differences in these measures between the two groups. 
This finding does not rule out the possibility of subtle early 
preHD changes, but does show that any such differences 
would be difficult to separate from natural variation among 
young adults. The measures used in this study, although 
comprehensive, were not exhaustive and other measures 
might have shown sensitivity in preHD. However, we 
maximised our sensitivity by selecting measures that were 
most likely to show early disease­related changes. The 
cognitive and neuropsychiatric batteries were selected 
based on previous work4,45 suggesting that these domains 
were most likely to show early deficits, as well as including 
novel assessments in CANTAB and EMOTICOM batteries 
shown to be highly sensitive in young cohorts. We also 
used state­of­the­art high­resolution 3T imaging with 
validated analysis methods to maximise our sensitivity to 
disease­related brain changes. The increasing availability 
of 7T imaging might provide yet more detailed evidence 
on the underlying Huntington’s disease pathology in 
the future. Longitudinal follow up of this cohort will be 
important to address these issues, while also providing 
further clarity on the biomarkers that are most suitable for 
clinical trials in such far­from­onset cohorts.
In summary, by identifying a cohort of preHD 
individuals with no detectable functional impairment but 
who begin to exhibit subtle elevations in select biological 
measures of neurodegeneration, we have high lighted a 
crucial point early in the disease process. Intervening at 
this stage might offer the prospect of delaying or pre­
venting further neurodegeneration while function is 
intact, giving gene carriers many more years of life with­
out impairment.
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